In the last trading session, 2,312,423 Millendo Therapeutics, Inc. (NASDAQ:MLND) shares changed hands as the company’s beta touched 0.43. With the company’s per share price at $1.52 changed hands at -$0.01 or -0.01% during last session, the market valuation stood at $28.95 Million. MLND’s last price was a discount, traded about -92.76% off its 52-week high of $2.93. The share price had its 52-week low at $0.918, which suggests the last value was 39.61% up since then. When we look at Millendo Therapeutics, Inc.’s average trading volume, we note the 10-day average is 2.73 Million shares, with the 3-month average coming to 1.94 Million.
Analysts gave the Millendo Therapeutics, Inc. (MLND) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 1 recommended MLND as a Hold, none felt it is a Buy and none rated the stock as Underweight. Millendo Therapeutics, Inc.’s EPS for the current quarter is expected to be -$0.36.
Millendo Therapeutics, Inc. (NASDAQ:MLND) trade information
Although MLND has turned red as seen at the end of in last trading. With action -0.65%, the performance over the past five days has been green. The jump to weekly highs of $1.55 on Friday, Jun 18 added 1.94% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.29%, with the 5-day performance at 0.11% in the green. However, in the 30-day time frame, Millendo Therapeutics, Inc. (NASDAQ:MLND) is 0.38% up. Looking at the short shares, we see there were 1.98 Million shares sold at short interest cover period of 1.02 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5, meaning bulls need an upside of 228.95% from its current market value. According to analyst projections, MLND’s forecast low is $5 with $5 as the target high. To hit the forecast high, the stock’s price needs a +228.95% upsurge from its current level, while the stock would need to tank 228.95% for it to hit the projected low.
Millendo Therapeutics, Inc. (MLND) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 45.6%. The 2021 estimates are for Millendo Therapeutics, Inc. earnings to increase by 40.6%, but the outlook for the next 5-year period is at 0% per year.
Millendo Therapeutics, Inc. (NASDAQ:MLND)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.28% of Millendo Therapeutics, Inc. shares while 37.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 39.67%. There are 41 institutions holding the Millendo Therapeutics, Inc. stock share, with NEA Management Company, LLC the top institutional holder. As of Mar 30, 2021, the company held 9.28% of the shares, roughly 1.77 Million MLND shares worth $2.12 Million.
Ikarian Capital, LLC holds the second largest percentage of outstanding shares, with 7.08% or 1.35 Million shares worth $1.62 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Extended Market Index Fund and Bridgeway Funds Inc-Small Cap Growth Fund. With 181671 shares estimated at $218.01 Thousand under it, the former controlled 0.95% of total outstanding shares. On the other hand, Bridgeway Funds Inc-Small Cap Growth Fund held about 0.86% of the shares, roughly 164.3 Thousand shares worth around $197.16 Thousand.